{
  "docId": "019dd923-622c-750b-8b98-08d95731b035",
  "docSlug": "4dea9707af58",
  "documentTitle": "AtriCure, Inc. (ATRC)",
  "authorId": "53_Kerrisdale_Capital",
  "authorName": "Kerrisdale Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2020-09-01 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 7,
  "pageCount": 34,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Research note discussing the technical advantages of PFA over RF/cryoablation and the diagnostic superiority of AcQMap over traditional mapping.",
  "elementsJson": [
    "paragraph",
    "bullet_list"
  ],
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b98-08d95731b035/7",
  "deckHref": "/decks/019dd923-622c-750b-8b98-08d95731b035",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b98-08d95731b035.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b98-08d95731b035#slide-7",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "We expect the first generation of these devices to hit EP labs within the next 3-4 years, dealing the final blow to any rationale for broad adoption of hybrid/minimally-invasive surgical ablation approaches.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0396-73da-b904-da5da61b3b8c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.11,
        "y": 0.09
      },
      "kind": "paragraph",
      "text": "The electroporation is tissue-specific – the pulsed electric fields can be calibrated so that they only impact the cardiac tissue, leaving the esophagus, proximal nerve cells, and any vasculature totally untouched.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43b7285a-aa24-4069-8ccd-717944828412",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.8,
        "x": 0.11,
        "y": 0.26
      },
      "kind": "paragraph",
      "text": "PFA has already been studied in a large number of trials, and continues to quickly gain credibility. We expect the first generation of these devices to hit EP labs within the next 3-4 years.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71df2a46-8af8-4e50-8ff2-6bb9f211c684",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.8,
        "x": 0.11,
        "y": 0.46
      },
      "kind": "paragraph",
      "text": "The other technology we believe will challenge the logic for minimally invasive surgical ablation is Acutus Medical's AcQMap system. Acutus' system is contactless and can generate a usable map of single points in time in less than 3 minutes.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9086c1b-336e-4e23-a692-be9dcee0a374",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.11,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "Acutus's technology is already commercialized, and PFA is headed there shortly. While we expect the uptake on AtriCure's Convergent procedure and the associated devices will be",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ceae1ec7-2a62-4009-b95e-607f56d2c95f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.8,
        "x": 0.11,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "Rapidity – electroporation allows for the creation of tissue-destroying lesions to large areas of the myocardium, essentially instantaneously.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee699162-3ab2-4939-a848-135e1d7a0b5f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 6,
      "beatId": "4e62a9ca-4c36-4797-a49e-21bad253e137",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Struggle",
      "beatSlug": "overcoming-monster-the-struggle",
      "evidence": "The document presents various critiques of AtriCure's business model and market prospects",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 5,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "ddc2fc5b-a109-4c3d-a59c-6071803a7a20",
      "evidence": "The document presents various critiques of AtriCure's business model and market prospects",
      "position": 0,
      "objective": "To identify patterns in AtriCure's business model and market prospects that indicate a flawed strategy",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.7,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}